South African Medical News

Back to Home Page

Print using browser
Puregon Inj, recombinant follicle-stimulating hormone (FSH) (MSD)

msdlogo






Dear Healthcare Professional

Merck Sharp & Dohme Corp. (“MSD”), a subsidiary of Merck & Co., Inc., has performed a portfolio review in South Africa and we would like to inform you that a business decision has been made to discontinue all strengths and package sizes of Puregon effective JANUARY 2019.

The company’s decision to delete these products is business related and not due to safety, efficacy, or quality issues.

A limited supply of Puregon remains in stock at the wholesalers and is available for order. Once this stock is depleted, however, there will be no further replenishment.


        * This is a drug - read the leaflet carefully before use.

        * Ask your doctor or pharmacist for further information.

For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority.

MSD is committed to providing the highest quality products and regrets any inconvenience this situation may cause.

MSD (Pty) Ltd. 117 - 16th Road, Halfway House, South Africa



You need to be logged in to see more details. Register Now!


Click here to visit the MSD website.....
Contact: Yvette Kilian, Director: Primary Care
Telephone: +27 (0) 11 655 3000
E-mail: yvette_kilian@merck.com
Date: Monday, March 4, 2019